Who owns Adaptimmune Therapeutics?
- Ticker: ADAP
- CUSIP Number: 00653a107
Tip: Access positions for across all investors
Analyze quarterly positions in Adaptimmune Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Adaptimmune Therapeutics stock
Who bought or sold Adaptimmune Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| EcoR1 Capital | 27M | $43M | 100% | Mar 2024 |
|
| NEA Management Company | 17M | $27M | 0% | Mar 2024 |
|
| Baillie Gifford & Co | 16M | $25M | 0% | Mar 2024 |
|
| Baker Bros. Advisors | 11M | $17M | -2% | Mar 2024 |
|
| Long Focus Capital Management | 11M | $17M | -12% | Mar 2024 |
|
| Partner Fund Management | 10M | $8.3M | 0% | Dec 2023 |
|
| MPM Asset Management | 5.6M | $8.8M | -12% | Mar 2024 |
|
| MPM Oncology Impact Management | 5.1M | $8.1M | 0% | Mar 2024 |
|
| Bank of America Corporation | 4.7M | $7.4M | -1% | Mar 2024 |
|
| Rock Springs Capital Management | 2.4M | $3.8M | -13% | Mar 2024 |
|
| FMR | 1.7M | $2.7M | 0% | Mar 2024 |
|
| Tang Capital Management | 1.4M | $2.3M | -67% | Mar 2024 |
|
| Jpmorgan Chase & Co | 915k | $1.4M | -1% | Mar 2024 |
|
| Millennium Management | 825k | $1.3M | 87% | Mar 2024 |
|
| Redmile Group | 716k | $1.1M | 0% | Mar 2024 |
|
| Cubist Systematic Strategies | 676k | $1.1M | 1853% | Mar 2024 |
|
| Acuitas Investments | 538k | $851k | 12% | Mar 2024 |
|
| Rathbones Brothers | 433k | $684k | 0% | Mar 2024 |
|
| Morgan Stanley | 373k | $590k | -82% | Mar 2024 |
|
| GSA Capital Partners | 370k | $585k | -27% | Mar 2024 |
|
| DAFNA Capital Management | 341k | $539k | -3% | Mar 2024 |
|
| Citadel Advisors | 315k | $498k | -91% | Mar 2024 |
|
| BlackRock | 290k | $458k | -77% | Mar 2024 |
|
| Key Client Fiduciary Advisors | 269k | $425k | -20% | Mar 2024 |
|
| Marshall Wace | 254k | $401k | 100% | Mar 2024 |
|
| UBS Group | 197k | $311k | 697% | Mar 2024 |
|
| Harbor Capital Advisors | 188k | $297k | 27% | Mar 2024 |
|
| Geode Capital Management | 118k | $186k | 0% | Mar 2024 |
|
| Captrust Financial Advisors | 112k | $177k | 549% | Mar 2024 |
|
| LPL Financial | 109k | $172k | 100% | Mar 2024 |
|
| Goldman Sachs Group | 108k | $170k | 573% | Mar 2024 |
|
| Marquette Asset Management | 99k | $156k | 0% | Mar 2024 |
|
| Atlantic Trust | 77k | $113k | 100% | Mar 2024 |
|
| Susquehanna International | 70k | $111k | -58% | Mar 2024 |
|
| Northern Trust | 58k | $91k | 0% | Mar 2024 |
|
| Wells Fargo & Company | 54k | $86k | -4% | Mar 2024 |
|
| Barclays | 50k | $79k | 0% | Mar 2024 |
|
| Two Sigma Advisers | 46k | $73k | -23% | Mar 2024 |
|
| Oppenheimer & Co | 44k | $69k | -36% | Mar 2024 |
|
| Wealth Enhancement Advisory Services | 32k | $51k | 0% | Mar 2024 |
|
| Main Street Financial Solutions | 31k | $49k | 0% | Mar 2024 |
|
| CSS | 31k | $49k | 0% | Mar 2024 |
|
| DLK Investment Management | 31k | $48k | 0% | Mar 2024 |
|
| Massey, Quick & Co | 30k | $47k | 0% | Mar 2024 |
|
| Janney Montgomery Scott | 30k | $47k | 0% | Mar 2024 |
|
| Prosperity Wealth Management | 27k | $42k | -7% | Mar 2024 |
|
| Hsbc Holdings | 27k | $19k | 2% | Dec 2023 |
|
| JTC Employer Solutions Trustee | 26k | $41k | 100% | Mar 2024 |
|
| Stifel Financial | 24k | $38k | -13% | Mar 2024 |
|
| Hunter Associates | 23k | $37k | 0% | Mar 2024 |
|
| Vontobel Holding | 23k | $36k | 100% | Mar 2024 |
|
| Group One Trading | 22k | $35k | 100% | Mar 2024 |
|
| Advisor Group Holdings | 19k | $30k | 208% | Mar 2024 |
|
| Commonwealth Equity Services | 16k | $26k | -2% | Mar 2024 |
|
| XTX Topco | 16k | $25k | 100% | Mar 2024 |
|
| Columbia Advisory Partners | 16k | $25k | 100% | Mar 2024 |
|
| Ballentine Partners | 15k | $23k | 100% | Mar 2024 |
|
| Two Sigma Investments | 15k | $23k | 100% | Mar 2024 |
|
| Procyon Private Wealth Partners | 13k | $21k | 100% | Mar 2024 |
|
| X-Square Capital | 11k | $14k | -59% | Mar 2024 |
|
| Rhumbline Advisers | 7.1k | $11k | 20% | Mar 2024 |
|
| Lindbrook Capital | 6.7k | $11k | 46% | Mar 2024 |
|
| Quadrant Capital | 6.3k | $9.9k | 100% | Mar 2024 |
|
| Wetzel Investment Advisors | 6.0k | $5.4k | 100% | Mar 2024 |
|
| Global Retirement Partners | 6.0k | $9.5k | 0% | Mar 2024 |
|
| Lazard Asset Management | 4.2k | $0 | -4% | Dec 2023 |
|
| Signature | 2.0k | $3.2k | 100% | Mar 2024 |
|
| Sandy Spring Bank | 1.1k | $1.7k | 0% | Mar 2024 |
|
| Federation des caisses Desjardins du Quebec | 785.00 | $1.2k | 100% | Mar 2024 |
|
| Royal Bank of Canada | 700.00 | $1.0k | 18% | Mar 2024 |
|
| Carmichael Hill & Associates | 525.00 | $830.025000 | 0% | Mar 2024 |
|
| HighMark Wealth Management | 287.00 | $453.000800 | 0% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 213.00 | $337.008600 | -90% | Mar 2024 |
|
| Investors Research Corp | 100.00 | $158.000000 | 0% | Mar 2024 |
|
Who sold out of Adaptimmune Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Syncona Portfolio | Dec 2023 | 1.4M | $1.1M |
| Jane Street | Dec 2023 | 98k | $77k |
| Hrt Financial | Dec 2023 | 60k | $47k |
| Virtu Financial | Dec 2023 | 28k | $23k |
| Newman Dignan & Sheerar | Dec 2023 | 23k | $18k |
| Qube Research & Technologies | Sep 2023 | 22k | $17k |
| ProShare Advisors | Sep 2023 | 14k | $11k |
| Douglas Lane & Associates | Dec 2023 | 11k | $8.7k |
| Raymond James & Associates | Dec 2023 | 10k | $8.1k |
| Tower Research Capital | Sep 2023 | 8.0k | $6.3k |
| Cutler | Dec 2023 | 1.4k | $1.0k |
| Simplex Trading | Dec 2023 | 300.00 | $0 |
| Advisory Services Network | Dec 2023 | 125.00 | $99.000000 |